Background: Chronic persistent pain as a result of terminal illness, either as a consequence
of the disease or the necessary treatment, is common in patients with cancer. For these …

Background: Intrathecal drug infusion therapy is usually considered when spinal-acting
analgesics or antispasmodics administered via the oral or transdermal routes fail to control …

Intrathecal drug delivery is an effective pain management option for patients with chronic
and cancer pain. The delivery of drugs into the intrathecal space provides superior …

In conclusion, complete assessment of a patient's physical, psychological, and social
characteristics, can guide practitioners in determining the appropriateness of initiating …

A substantial number of patients with cancer suffer considerable pain at some point during
their disease, and approximately 25% of cancer patients die in pain. Providing effective pain …

BACKGROUND: The safety and efficacy of intrathecal drug delivery systems (IDDSs) for the
treatment of cancer-related pain have been demonstrated in randomized controlled clinical …

Pain is prevalent in advanced malignancies; however, some patients cannot get adequate
pain relief by conservative routes of analgesic administration or experience serious side …

Objectives Intrathecal drug delivery systems (IDDS) and spinal cord stimulation (SCS) have
been proposed and assessed for the management of cancer pain; however, such treatments …

PURPOSE: Implantable intrathecal drug delivery systems (IDDSs) have been used to
manage refractory cancer pain, but there are no randomized clinical trial (RCT) data …

Objective. The increasing incidence of cancer survivorship has shifted treatment of cancer-
related pain from short-term analgesia to long-term chronic pain management. As a result …